172 related articles for article (PubMed ID: 16564141)
21. Chemical profile of counterfeit buprenorphine vials seized in Tehran, Iran.
Soltaninejad K; Faryadi M; Akhgari M; Bahmanabadi L
Forensic Sci Int; 2007 Oct; 172(2-3):e4-5. PubMed ID: 17646070
[TBL] [Abstract][Full Text] [Related]
22. Integrating nine prescription opioid analgesics and/or four signal detection systems to summarize statewide prescription drug abuse in the United States in 2007.
Schneider MF; Bailey JE; Cicero TJ; Dart RC; Inciardi JA; Parrino M; Muñoz A
Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):778-90. PubMed ID: 19536784
[TBL] [Abstract][Full Text] [Related]
23. Trends in the use and abuse of branded and generic extended release oxycodone and fentanyl products in the United States.
Cicero TJ; Inciardi JA; Surratt H
Drug Alcohol Depend; 2007 Dec; 91(2-3):115-20. PubMed ID: 17590285
[TBL] [Abstract][Full Text] [Related]
24. Non-medical use and abuse of commonly prescribed medications.
Riggs P
Curr Med Res Opin; 2008 Mar; 24(3):869-77. PubMed ID: 18267053
[TBL] [Abstract][Full Text] [Related]
25. The burden of the nonmedical use of prescription opioid analgesics.
Gilson AM; Kreis PG
Pain Med; 2009 Jul; 10 Suppl 2():S89-100. PubMed ID: 19691688
[TBL] [Abstract][Full Text] [Related]
26. Prescription opioid abuse among enrollees into methadone maintenance treatment.
Rosenblum A; Parrino M; Schnoll SH; Fong C; Maxwell C; Cleland CM; Magura S; Haddox JD
Drug Alcohol Depend; 2007 Sep; 90(1):64-71. PubMed ID: 17386981
[TBL] [Abstract][Full Text] [Related]
27. Abuse and diversion of buprenorphine sublingual tablets and film.
Lavonas EJ; Severtson SG; Martinez EM; Bucher-Bartelson B; Le Lait MC; Green JL; Murrelle LE; Cicero TJ; Kurtz SP; Rosenblum A; Surratt HL; Dart RC
J Subst Abuse Treat; 2014 Jul; 47(1):27-34. PubMed ID: 24680219
[TBL] [Abstract][Full Text] [Related]
28. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse.
Butler SF; Budman SH; Licari A; Cassidy TA; Lioy K; Dickinson J; Brownstein JS; Benneyan JC; Green TC; Katz N
Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1142-54. PubMed ID: 18932173
[TBL] [Abstract][Full Text] [Related]
29. The underrecognized toll of prescription opioid abuse on young children.
Bailey JE; Campagna E; Dart RC;
Ann Emerg Med; 2009 Apr; 53(4):419-24. PubMed ID: 18774623
[TBL] [Abstract][Full Text] [Related]
30. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
Mammen K; Bell J
Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
[TBL] [Abstract][Full Text] [Related]
31. Psychoactive drug abuse in older adults.
Simoni-Wastila L; Yang HK
Am J Geriatr Pharmacother; 2006 Dec; 4(4):380-94. PubMed ID: 17296542
[TBL] [Abstract][Full Text] [Related]
32. Opioid dependence: rationale for and efficacy of existing and new treatments.
Fiellin DA; Friedland GH; Gourevitch MN
Clin Infect Dis; 2006 Dec; 43 Suppl 4():S173-7. PubMed ID: 17109303
[TBL] [Abstract][Full Text] [Related]
33. Association between non-medical and prescriptive usage of opioids.
Dasgupta N; Kramer ED; Zalman MA; Carino S; Smith MY; Haddox JD; Wright C
Drug Alcohol Depend; 2006 Apr; 82(2):135-42. PubMed ID: 16236466
[TBL] [Abstract][Full Text] [Related]
34. Active surveillance of abused and misused prescription opioids using poison center data: a pilot study and descriptive comparison.
Hughes AA; Bogdan GM; Dart RC
Clin Toxicol (Phila); 2007; 45(2):144-51. PubMed ID: 17364631
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers.
Butler SF; Benoit C; Budman SH; Fernandez KC; McCormick C; Venuti SW; Katz N
Harm Reduct J; 2006 Feb; 3():5. PubMed ID: 16457713
[TBL] [Abstract][Full Text] [Related]
36. Managing opioid addiction with buprenorphine.
Donaher PA; Welsh C
Am Fam Physician; 2006 May; 73(9):1573-8. PubMed ID: 16719249
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of a transdermal buprenorphine formulation in opioid detoxification.
Lanier RK; Umbricht A; Harrison JA; Nuwayser ES; Bigelow GE
Addiction; 2007 Oct; 102(10):1648-56. PubMed ID: 17854341
[TBL] [Abstract][Full Text] [Related]
38. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.
Alho H; Sinclair D; Vuori E; Holopainen A
Drug Alcohol Depend; 2007 Apr; 88(1):75-8. PubMed ID: 17055191
[TBL] [Abstract][Full Text] [Related]
39. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004.
Cicero TJ; Inciardi JA; Adams EH; Geller A; Senay EC; Woody GE; Muñoz A
Pharmacoepidemiol Drug Saf; 2005 Dec; 14(12):851-9. PubMed ID: 15892169
[TBL] [Abstract][Full Text] [Related]
40. National drug control policy and prescription drug abuse: facts and fallacies.
Manchikanti L
Pain Physician; 2007 May; 10(3):399-424. PubMed ID: 17525776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
